Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06203054 · ClinicalTrials.gov registry record · NA
CLIP-IT Post-Market Study
A NA study of Left Atrial Appendage Exclusion, sponsored by Medtronic Cardiac Surgery.
- Active
- Registry status
- NA
- Development phase
- 150
- Enrollment target
- 15
- Study locations
NCT06203054: Active NA study of Left Atrial Appendage Exclusion, sponsored by Medtronic Cardiac Surgery.
NCT06203054 is a NA study of Left Atrial Appendage Exclusion that is active but no longer recruiting, run by Medtronic Cardiac Surgery. The registered enrollment target is 150 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (89% lower). The trial reports 15 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06203054, a NA study of Left Atrial Appendage Exclusion, is active but no longer recruiting, sponsored by Medtronic Cardiac Surgery.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 150 participants
- Enrollment target
- 15
- Study locations
Study Summary
The purpose of this study is to collect post-market clinical evidence on performance and clinical outcomes of the Penditure™ Left Atrial Appendage (LAA) Exclusion System in subjects undergoing concomitant cardiac surgery.
Primary Outcome
The primary efficacy endpoint is the rate of successful exclusion of the left atrial appendage (LAA) from the heart defined as the absence of residual communication (≤ 3 mm residual contrast communication) between the left atrium (LA) and the left atrial appendage (LAA). For those successfully placed devices, exclusion will be confirmed at 3 months as demonstrated by multi-detector computed tomography (MDCT) scan.
Conditions Studied
Interventions
- DEVICE Penditure™ Left Atrial Appendage (LAA) Exclusion System
Study Locations (15)
Pennsylvania
- UPMC Pinnacle Harrisburg Campus - Harrisburg
- University of Pittsburgh Medical Center UPMC Presbyterian - Pittsburgh
- Lankenau Institute for Medical Research - Wynnewood
Michigan
- University of Michigan Health System - Ann Arbor
- Corewell Health - Grand Rapids
Ohio
- University Hospitals Cleveland Medical Center - Cleveland
- ProMedica Toledo Hospital - Toledo
Georgia
- Emory Saint Joseph's Hospital - Atlanta
Illinois
- Northwestern Memorial Hospital - Chicago
Indiana
- Ascension St. Vincent Heart Center - Carmel
Minnesota
- Mayo Clinic Saint Marys Campus - Rochester
Missouri
- Barnes Jewish Hospital - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2024-02-26 |
| Est. Completion | 2029-02 |
| Phase | NA |
What the registry record for NCT06203054 still lists
NCT06203054 is an interventional study that assigns participants to a tested intervention. The registered 150 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (89% lower).
The record links to 1 condition, with Left Atrial Appendage Exclusion appearing as the primary indexed condition, and to 1 intervention - of which Penditure™ Left Atrial Appendage (LAA) Exclusion System is the first listed.
NCT06203054 lists 15 locations in 11 states (Pennsylvania, Michigan, Ohio).
Frequently Asked Questions
What is clinical trial NCT06203054 about?
NCT06203054 is a clinical study titled "CLIP-IT Post-Market Study". The purpose of this study is to collect post-market clinical evidence on performance and clinical outcomes of the Penditure™ Left Atrial Appendage (LAA) Exclusion System in subjects undergoing concomitant cardiac surgery.
What is the current status of trial NCT06203054?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 150 participants. The study started on 2024-02-26. Estimated completion is 2029-02.
What conditions does trial NCT06203054 study?
This clinical trial studies the following conditions: Left Atrial Appendage Exclusion.
What interventions are being tested in trial NCT06203054?
The interventions under investigation include: Penditure™ Left Atrial Appendage (LAA) Exclusion System (DEVICE).
Who is sponsoring clinical trial NCT06203054?
This trial is sponsored by Medtronic Cardiac Surgery, which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06203054 being conducted?
This trial has 15 study locations across Georgia, Illinois, Indiana, Michigan, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06203054's enrollment target sits among peer trials
150 661st of 2000 higher than 1,299 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00412594 · 150 participants · Phase 2
Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia
- NCT01484730 · 150 participants
A Pilot Study to Evaluate Multi-Spectral and Laser Speckle Imaging and Multiphoton Microscopy During Vascular Occlusion
- NCT01985919 · 150 participants
Protocol for Facilitating the Acquisition of Research Bone Marrow and Blood Samples
- NCT02016248 · 150 participants · NA
SBRT Boost for Unfavorable Prostate Cancer'
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI